Description |
Ceftolozane is a semi-synthetic beta-lactam antibiotic. It was approved by the FDA in January 2015 for use in combination with tazobactam for the treatment of:
-Complicated Intra-abdominal Infections, used in combination with metronidazole.
-Complicated Urinary Tract Infections, including Pyelonephritis.
Ceftolozane/tazobactam is marketed under the brand name Zerbaxa™ by Cubist Pharmaceuticals U.S, which effective January 22, 2015, is now a wholly owned subsidiary of Merck & Co., Inc.
|
